Cefepime-Taniborbactam

cefepime-taniborbactam photo pending

Page last updated August 2023, if cefepime-taniborbactam is FDA approved this page will be updated

KEY POINTS

Cefepime is a fourth-generation cephalosporin and beta-lactam antibiotic
Taniborbactam is a boronic acid containing beta-lacatamase inhibitor
- Taniborbactam has been shown to be able to inhibit enzyme from Ambler class A, B, C, and D
  - Class B enzymes are a major area of need and taniborbactam can inhibit VIM, NDM, SPM-1, and GIM-1 (but not IMP)
Adding taniborbactam as a beta-lactamase to cefepime can expand the actvitity of cefepime by preventing it’s degradation by beta-lactamase enzymes certain drug-resistant bacteria produce
- Cefepime-taniborbactam may be an option versus carbapenem-resistant Enterobacterales or Pseudomonas aeruginosa, including some bacteria that are resistant to ceftazidime-avibactam (Avycaz)
Not FDA approved for any indication as of August 2023
- Has an NDA that has been accepted by the FDA as of August 2023
- Being investigated by Venatorx Pharma
  - Being studied versus meropenem for complicated urinary tract infections (cUTIs) – (CERTAIN-1 study)
  - Being studied for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) – (CERTAIN-2 study)
- Potential FDA approval is anticipated for early 2024 at earliest, if it progresses to being approved #BadBugsNeedDrugs

RESOURCES